Profiel
Konrad Glund is the founder of Vivoryon Therapeutics NV, which was founded in 1997.
He held the title of Chief Executive Officer from 2006 to 2018.
Dr. Glund is also the founder of IFB Halle GmbH.
He previously worked as Vice President-Corporate Development at Prosidion Ltd. and as a Principal at Martin-Luther-Universität Halle-Wittenberg.
Dr. Glund earned a doctorate degree from Martin-Luther-Universität Halle-Wittenberg.
Eerdere bekende functies van Konrad Glund
| Bedrijven | Functie | Einde |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Algemeen Directeur | 30-04-2018 |
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Corporate Officer/Principal | - |
Martin-Luther-Universität Halle-Wittenberg
Martin-Luther-Universität Halle-Wittenberg Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
IFB Halle GmbH | Algemeen Directeur | - |
Opleiding van Konrad Glund
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Manufactures products for treatment of metabolic diseases | Health Technology |
Vivoryon Therapeutics NV
Vivoryon Therapeutics NV Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that is engaged in the research and development of new therapeutic products for the treatment of Alzheimer disease | Commercial Services |
Martin-Luther-Universität Halle-Wittenberg
Martin-Luther-Universität Halle-Wittenberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IFB Halle GmbH |
















